🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Biotechnological Requirements for Patient Monitoring in Gene Therapies medhealthoutlook.com/biotechnologic… Oscar Segurado Oscar Segurado, MD PhD ASC Therapeutics ASC Therapeutics #tech #technology #CRO #clinicalresearch #Biotechnological #bio

Looking forward to our Workshop on May 22 allogeneic-cell-therapies.com

Key drivers of our successful clinical programs clinicalleader.com/doc/assessing-…

Establish robust internal communication channels to ensure everyone can express opinions, ask questions and feel trusted and valued forbes.com/sites/forbeste…

Clinical Leader Live’s interactive webinar on how ASC Therapeutics and other sponsors are adapting to DCTs … hybrid, virtual, remote, home-based,… Register for free here: event.on24.com/wcc/r/4314211/…

Elated to have our paper on Cell Therapies for GVHD published in Frontiers in Immunology! frontiersin.org/articles/10.33…

Our publication is now available OPEN ACCESS: Novel therapies for graft versus host disease with a focus on cell therapies frontiersin.org/articles/10.33…

Learn about Decentralized Clinical Trials in this Clinical Leader Webinar youtu.be/N8D28t_eOgY

A personalized medicine approach through the combination of single biomarkers to develop signatures with AI, proven safe and effective in multiple oncology studies, still requires a significant effort to accelerate its adoption as standard of care news-medical.net/news/20231024/…

Our board member professor Behnam Sadeghi, Karolinska University Sweden, and our CEO Ruhong Jiang were keynote speaker and panelist at the 5th World Science and Technology Forum in Shenzen, China. Discussed our IND-cleared allogeneic cell therapy for GVHD

Hemophilia News Today highlights our potentially more durable and affordable second-generation gene therapy ASC618 in people with hemophilia A. hemophilianewstoday.com/news/dosing-be…

Ever wondered how far we’ve truly come in the realm of gene and cell therapies, and where we’re headed next? This captivating conversation with Oscar Segurado, the CMO of ASC Therapeutics, will satisfy your curiosity vial.com/blog/podcast/f…

Thanks, Charles Cormier, for this fun and inspiring interview. Always glad to talk about synthetic medicine and the mind-antibody connection youtu.be/dtAnB_GHmbU?si…

link.springer.com/article/10.100…

The immunological revolution of cell-based therapies for autoimmune disorders has just started biopharmadive.com/news/lupus-cel…

Many patients with metastatic cancer have died, are dying and will die if we don’t replace the conventional way of classifying metastatic cancers according to their organ of origin and embrace AI-driven molecular, cellular and protein fingerprinting nature.com/articles/d4158…

Congratulations to the editors and fellow authors for the culmination of this extraordinary effort to coalesce industry perspectives on the development of gene therapies!

… the lifetime cost for patients with severe Hemophilia A is over $21 million… biospace.com/article/gene-t…

Join me at the Chief Medical Officer Summit 360˚ in Boston on April 17-18! As a CMO, I am excited to discuss managing and motivating biotech teams while networking with like-minded professionals. Looking forward to gaining fresh insights and meeting fellow CMOs at #CMO360